{"disease":{"id":"ebv-associated-malignancies","name":"ebv associated malignancies"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07532746","title":"A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":55,"lead_sponsor_name":"Kousai Bio Co., Ltd.","has_results":false},{"nct_id":"NCT03988582","title":"Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}